Colorectal

No significant OS disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for CRC peritoneal metastases, according to long-term survival data.
Despite having high-risk features, most patients receiving first-line encorafenib plus binimetinib and cetuximab for BRAFV600E+ mCRC in the ANCHOR CRC trial had tumor regression.
Study findings suggest a regimen comprising nivolumab and radical surgery after chemoradiotherapy as a candidate therapy for locally advanced, MSS and MSI-H CRC.
When a plasma-based assay is being used to detect RAS status in patients with mCRC and lung or peritoneal metastasis alone, the maximum diameter and number of lesions should be carefully considered.
Elena Elez, MD, PhD, explains how to refine the selection of adjuvant treatment for stage II colorectal cancer.
Cathy Eng, MD, FACP, FASCO, discusses the latest developments in anal cancer over the past 12 months.
Axel Grothey, MD; Josep Tabernero, MD, PhD; and Scott Kopetz, MD, PhD, FACP, discuss the findings and clinical significance of the BEACON CRC trial.
Flexible regorafenib dosing is promising as an alternative therapy option for patients with metastatic CRC, according to results from the REARRANGE trial presented for the first time at the ESMO 21st…
Stay in the know.
OncNet Newsletter